CD8A and melanoma: More importantly, pre-treatment of melanoma cells with either IRE1α inhibitor STF-083010, MKC8866 or NF-κB inhibitor BAY-11-7085 (STF-083010, 10 μM for both A2058 and A375; MKC8866, 0.5 μM for both A2058 and A375; BAY-11-7085, 1 μM for both A2058 and A375) could reverse the above-mentioned alteration of CD8+T cells-mediated killing capacity of melanoma cells (Fig. 5A-H; Additional file 1: Fig. S10A-H; Additional file 1: S11A-H).